• Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%
• Operating cash flow of $579 million
• Diluted earnings per share of $2.48; non-GAAP diluted earnings per share of $2.37

Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Revenue increased by 8% to $1.3 billion, up 9% on a constant currency basis, driven by increased demand for sleep devices, masks, and solid growth in the Residential Care Software business. Gross margin improved 140 basis points to 59.3%, and non-GAAP gross margin improved 140 basis points to 59.9%, due to manufacturing and logistics efficiencies as well as favorable product mix. Income from operations increased 14%, and non-GAAP income from operations was up 13%. Net income for the quarter was $365 million, and diluted earnings per share was $2.48. Non-GAAP net income increased by 11% to $349 million, and non-GAAP diluted earnings per share increased by 11% to $2.37. Operating cash flow for the quarter was $579 million. During the quarter, Resmed announced the availability of its home sleep apnea test, NightOwl, across the United States, unveiled the findings of its fifth annual Global Sleep Survey, and announced a comprehensive brand evolution. The company was also awarded as one of the 'Top 100 Global Innovators' from LexisNexis.

Resmed expects to deliver strong financial performance in fiscal year 2025, with revenue growth of 8-10% and non-GAAP earnings per share growth of 10-12% compared to the prior year.

Resmed remains focused on addressing the global sleep health crisis, driving increased patient flow through education and awareness outreach, and continuing to innovate and deliver best-in-class products and software solutions to improve the lives of people with sleep and breathing health issues.